THE USE OF RITUXIMAB TO TREAT IGG4 RELATED DISEASE INDUCED CARDIOMYOPATHY

Dantwan Smith,Frank McGrew,John Prather,Christopher L. Smith,Jennifer Nickol,Thomas Flautt,Theodore Richards,Linnea Lebaron,Dakshin Gangadharamurthy,Likhitesh Jaikumar,Alison Spangler,Wittmann Murphy

THE USE OF RITUXIMAB TO TREAT IGG4 RELATED DISEASE INDUCED CARDIOMYOPATHY

2020

Dantwan Smith
Frank McGrew
John Prather
Christopher L. Smith
Jennifer Nickol
Thomas Flautt
Theodore Richards
Linnea Lebaron
Dakshin Gangadharamurthy
Likhitesh Jaikumar
Alison Spangler
Wittmann Murphy

Rituximab is a chimeric monoclonal antibody against the protein CD20 which is predominantly found on the surface of B cells. Malignant B cells express higher levels of CD20. Rituximab not only induces cellular apoptosis but also down regulates the B cell receptor and mediates antibody dependent

Keywords:

Cardiomyopathy
Diabetes mellitus
Cardiology
Medicine
IgG4-related disease
Rituximab
Internal medicine
Monoclonal antibody
Cancer research
Apoptosis
CD20
B-cell receptor
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations